Search - tctmd.com

Displaying 21 - 40 of 62

Sort: Relevancy | Date

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

Large Smartwatch Study Confirms AF in Most Patients Who Seek Care: mAF-App II

News Conference News ACC 2022

Large Smartwatch Study Confirms AF in Most Patients Who Seek Care: mAF-App II

Yael L. Maxwell

April 07, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

New STRENGTH Analysis Revives Omega-3 Debate

News Conference News ACC 2021

New STRENGTH Analysis Revives Omega-3 Debate

May 20, 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

News Conference News ACC 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

May 17, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

May 15, 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

News Conference News ACC 2021

PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI

May 15, 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

News Conference News ACC 2021

ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI

Yael L. Maxwell

May 15, 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

May 15, 2021

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

News Conference News ACC 2020

LAAO Registry: Safety of Watchman Looks Good in First Years of Rollout

April 06, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

March 29, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presentation ACC 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presenter: Renato Lopes

March 18, 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.